Eren Tunc, Burcu Busra, Tombalak Ercument, Ozdemir Tugrul, Leblebici Metin, Ozemir Ibrahim Ali, Ziyade Sedat, Alimoglu Orhan
Department of General Surgery, School of Medicine, Istanbul Medeniyet University Goztepe Training & Research Hospital, Dr. Erkin Street, Kadikoy, 34730, Istanbul, Turkey.
Department of Thoracic Surgery (Medical Statistics), School of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
J Gastrointest Surg. 2016 Jun;20(6):1231-8. doi: 10.1007/s11605-016-3114-2. Epub 2016 Feb 29.
Glasgow prognostic score (GPS) has been found to be a useful tool in various cancer types. Our aim was to evaluate the significance of GPS in patients operated on for colorectal cancer (CRC). Patients with CRC who underwent radical resections between April 2010 and January 2015 were retrospectively evaluated. GPS was estimated based on the preoperative measurement of C-reactive protein and serum albumin levels. Data including demographics, laboratory and pathological parameters, surgical outcomes, and late-term follow-up results were analyzed. The study group of 115 patients consisted of 51 (44 %) women and 64 (56 %) men with a median age of 66 (range 32-91) years. The mean follow-up period was 20 (range 7-41) months. Tumor size and wound infection rates were significantly increased in patients with higher GPS (p = 0.019 and p = 0.003, respectively). According to multivariate analyses, CEA and GPS were found to be independent risk factors significantly effecting mortality (p = 0.001 and p = 0.009, respectively). At the end of the late-term follow-up period, it was detected that cancer-specific survival significantly decreased as the GPS increased (p = 0.016). The GPS is a significant prognostic factor in CRC and should be included in the routine preoperative assessment of all surgically treated CRC patients.
格拉斯哥预后评分(GPS)已被证明是多种癌症类型中一种有用的工具。我们的目的是评估GPS在接受结直肠癌(CRC)手术患者中的意义。对2010年4月至2015年1月期间接受根治性切除的CRC患者进行回顾性评估。GPS根据术前测量的C反应蛋白和血清白蛋白水平进行估算。分析了包括人口统计学、实验室和病理参数、手术结果以及晚期随访结果等数据。研究组115例患者中,女性51例(44%),男性64例(56%),中位年龄66岁(范围32 - 91岁)。平均随访期为20个月(范围7 - 41个月)。GPS较高的患者肿瘤大小和伤口感染率显著增加(分别为p = 0.019和p = 0.003)。根据多因素分析,癌胚抗原(CEA)和GPS被发现是显著影响死亡率的独立危险因素(分别为p = 0.001和p = 0.009)。在晚期随访期结束时,发现随着GPS升高,癌症特异性生存率显著降低(p = 0.016)。GPS是CRC的一个重要预后因素,应纳入所有接受手术治疗的CRC患者的常规术前评估中。